MENU
+Compare
BBP
ETF ticker: NYSE ARCA
AS OF
Aug 8 closing price
Price
$62.93
Change
-$0.44 (-0.69%)
Net Assets
25.24M

BBP stock forecast, quote, news & analysis

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index... Show more

Category: #Health
BBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for BBP with price predictions
Aug 08, 2025

BBP's RSI Indicator leaves overbought zone

The 10-day RSI Indicator for BBP moved out of overbought territory on July 11, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 instances where the indicator moved out of the overbought zone. In of the 24 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Moving Average Convergence Divergence Histogram (MACD) for BBP turned negative on July 28, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BBP broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 07, 2025. You may want to consider a long position or call options on BBP as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for BBP moved above the 200-day moving average on August 08, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BBP advanced for three days, in of 310 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 220 cases where BBP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Intra-Cellular Therapies (NASDAQ:ITCI), Sarepta Therapeutics (NASDAQ:SRPT), BioCryst Pharmaceuticals (NASDAQ:BCRX).

Industry description

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.

Market Cap

The average market capitalization across the Virtus LifeSci Biotech Products ETF ETF is 13.87B. The market cap for tickers in the group ranges from 145.14M to 155.17B. AMGN holds the highest valuation in this group at 155.17B. The lowest valued company is IRWD at 145.14M.

High and low price notable news

The average weekly price growth across all stocks in the Virtus LifeSci Biotech Products ETF ETF was 2%. For the same ETF, the average monthly price growth was 1%, and the average quarterly price growth was 2%. YMAB experienced the highest price growth at 88%, while TGTX experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Virtus LifeSci Biotech Products ETF ETF was -10%. For the same stocks of the ETF, the average monthly volume growth was -16% and the average quarterly volume growth was 5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 62
P/E Growth Rating: 80
Price Growth Rating: 50
SMR Rating: 81
Profit Risk Rating: 79
Seasonality Score: -15 (-100 ... +100)
View a ticker or compare two or three
BBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
501 Madison Avenue, Suite 501New YorkNew York
Phone
(212) 593-4383
Web
N/A